Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044339831> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2044339831 endingPage "585" @default.
- W2044339831 startingPage "582" @default.
- W2044339831 abstract "Background:The common treatment for antineutrophil cytoplasmic autoantibody (ANCA)–associated renal vasculitis is oral cyclophosphamide (CYC)-corticosteroid combination therapy. However, there are serious complications associated with long-term use of CYC. In this study, we investigate the efficacy of a purine synthesis inhibitor, mizoribine, for patients at high risk for relapse. Methods:Our study included 5 patients, 4 patients with myeloperoxidase (MPO)-ANCA-associated renal vasculitis and 1 patient with proteinase 3 (PR3)-ANCA-associated renal vasculitis, who had achieved remission through treatment with methylprednisolone pulse therapy, corticosteroids, and CYC. When their ANCA titers were found to be greater than normal range after remission status, mizoribine treatment was initiated. Results:Median time from initial treatment to first administration of mizoribine was 40.0 months (range, 24 to 51 months). Median follow-up was 13.0 months (range, 6 to 16 months). Before initiation of mizoribine treatment, no patient had experienced relapse and ANCA titers were less than the detectable range in all patients at 3 months before mizoribine administration. When mizoribine administration was started, ANCA titers were elevated in all patients (median MPO-ANCA, 101 ELISA units [EU]; range, 65 to 154 EU; PR3-ANCA, 55 EU), but no new symptoms or signs of relapse were noted. After 2 months of mizoribine treatment, only 1 patient had experienced a relapse; however, ANCA titers had decreased in all other patients and normalized in 3 patients. No adverse effects appeared in any patient. Conclusion:Considering the balance between suppression of disease activity and adverse effects of treatment, mizoribine may be useful for preemptive treatment for patients with ANCA-associated renal vasculitis at high risk for relapse." @default.
- W2044339831 created "2016-06-24" @default.
- W2044339831 creator A5051953810 @default.
- W2044339831 date "2004-11-01" @default.
- W2044339831 modified "2023-09-23" @default.
- W2044339831 title "ANCA-associated vasculitis: pathogenesis revisited" @default.
- W2044339831 cites W1483606862 @default.
- W2044339831 cites W1981778251 @default.
- W2044339831 cites W2037239628 @default.
- W2044339831 cites W2041565487 @default.
- W2044339831 cites W2045410073 @default.
- W2044339831 cites W2070854468 @default.
- W2044339831 cites W2098605310 @default.
- W2044339831 cites W2111806443 @default.
- W2044339831 cites W2111928792 @default.
- W2044339831 cites W2141637850 @default.
- W2044339831 cites W2150612435 @default.
- W2044339831 cites W2156063426 @default.
- W2044339831 cites W2156199940 @default.
- W2044339831 cites W2157356913 @default.
- W2044339831 cites W2162725007 @default.
- W2044339831 cites W2315283513 @default.
- W2044339831 cites W4233885503 @default.
- W2044339831 doi "https://doi.org/10.1016/j.autrev.2004.07.026" @default.
- W2044339831 hasPublicationYear "2004" @default.
- W2044339831 type Work @default.
- W2044339831 sameAs 2044339831 @default.
- W2044339831 citedByCount "1" @default.
- W2044339831 countsByYear W20443398312023 @default.
- W2044339831 crossrefType "journal-article" @default.
- W2044339831 hasAuthorship W2044339831A5051953810 @default.
- W2044339831 hasConcept C126322002 @default.
- W2044339831 hasConcept C159654299 @default.
- W2044339831 hasConcept C163764329 @default.
- W2044339831 hasConcept C197934379 @default.
- W2044339831 hasConcept C203014093 @default.
- W2044339831 hasConcept C2776015282 @default.
- W2044339831 hasConcept C2776694085 @default.
- W2044339831 hasConcept C2776755627 @default.
- W2044339831 hasConcept C2777882293 @default.
- W2044339831 hasConcept C2778910314 @default.
- W2044339831 hasConcept C2779134260 @default.
- W2044339831 hasConcept C71924100 @default.
- W2044339831 hasConcept C90924648 @default.
- W2044339831 hasConceptScore W2044339831C126322002 @default.
- W2044339831 hasConceptScore W2044339831C159654299 @default.
- W2044339831 hasConceptScore W2044339831C163764329 @default.
- W2044339831 hasConceptScore W2044339831C197934379 @default.
- W2044339831 hasConceptScore W2044339831C203014093 @default.
- W2044339831 hasConceptScore W2044339831C2776015282 @default.
- W2044339831 hasConceptScore W2044339831C2776694085 @default.
- W2044339831 hasConceptScore W2044339831C2776755627 @default.
- W2044339831 hasConceptScore W2044339831C2777882293 @default.
- W2044339831 hasConceptScore W2044339831C2778910314 @default.
- W2044339831 hasConceptScore W2044339831C2779134260 @default.
- W2044339831 hasConceptScore W2044339831C71924100 @default.
- W2044339831 hasConceptScore W2044339831C90924648 @default.
- W2044339831 hasIssue "7-8" @default.
- W2044339831 hasLocation W20443398311 @default.
- W2044339831 hasOpenAccess W2044339831 @default.
- W2044339831 hasPrimaryLocation W20443398311 @default.
- W2044339831 hasRelatedWork W1441973778 @default.
- W2044339831 hasRelatedWork W1556689649 @default.
- W2044339831 hasRelatedWork W184667369 @default.
- W2044339831 hasRelatedWork W1999635097 @default.
- W2044339831 hasRelatedWork W2045927732 @default.
- W2044339831 hasRelatedWork W2155448421 @default.
- W2044339831 hasRelatedWork W2341047070 @default.
- W2044339831 hasRelatedWork W2789420638 @default.
- W2044339831 hasRelatedWork W2925031891 @default.
- W2044339831 hasRelatedWork W40526389 @default.
- W2044339831 hasVolume "3" @default.
- W2044339831 isParatext "false" @default.
- W2044339831 isRetracted "false" @default.
- W2044339831 magId "2044339831" @default.
- W2044339831 workType "article" @default.